In cooperation with life sciences news platform BioVox, Member Spotlight introduces members of MEDVIA, detailing their services and innovations.
OHMX.bio provides innovative omics solutions using state-of-the-art sequencing and mass spectrometry platforms. Specializing in expression analysis (RNA-seq and RIBO-seq) and epigenetic profiling, as well as companion diagnostics, the company uses second- and third-generation sequencing technology to enable scientific insights and build assays for better drug and therapy development. With both a wet lab and dry lab in house, OHMX.bio offers a full-circle service to biotech and pharma partners.
Science has come a very long way since the first sequencing of the human genome in 2003. Technological advancements have opened up a wealth of possibilities in various omics fields – such as genomics, transcriptomics, and proteomics – that have enabled dramatic breakthroughs in health and life sciences.
With this rise in omics studies, the demand for faster, better sequencing solutions has boomed, and new companies have arisen to meet the challenge. OHMX.bio is one such company, established in 2019 as a spin-off of Ghent University. Gerben Menschaert, Co-founder and CSO, explains the motivation behind the founding of the company:
“Omics research is no longer a niche field – it is being used across many different sectors and at different stages of research. However, many companies lack the infrastructure or experience to work with these expensive and …
Please visit the BioVox website to read the rest of the article